

**RECEIVED  
CENTRAL FAX CENTER**

JUN 15 2006

**FAX**



GlaxoSmithKline

To Attn: Corrected Filing Receipt  
Company USPTO  
Fax (571) 273-8300  
From Patty Wilson  
Tel 1-919-483-1007; Facsimile: 1-919-483-7977  
E-mail patricia.t.wilson@gsk.com  
Date June 15, 2006 Pages including cover 4  
Subject Application of: Barvian et al.  
U.S. Serial No.: 10/552,232  
Attorney Docket No. PR60211USw

GlaxoSmithKline  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709

Tel: 919 483 2100  
www.gsk.com

Attached: Request for Corrected Filing Receipt;  
Copy of Filing Receipt.

**Certificate of Transmission by Facsimile (37 CFR 1.8)**

I hereby certify that this correspondence is being facsimile  
transmitted on June 15, 2006.

Patty Wilson  
Patty Wilson

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Atty. Dkt. No. PR60211USw

**RECEIVED  
CENTRAL FAX CENTER**

JUN 15 2006

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Kevin K. Barvian et al.  
 Serial No.: 10/552,232  
 Filed: October 7, 2005  
 Title: Heterocyclic MCHR1 Antagonists

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

**REQUEST FOR CORRECTED FILING RECEIPT**

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested. A copy of the Filing Receipt is attached to show the corrections.
2. There is an error with respect to the following data, which is:

 incorrectly entered

and/or

 omitted.**Error in**

1.  Applicant's name
2.  Applicant's address
3.  Title
4.  Filing date
5.  Serial Number
6.  Foreign/PCT Application Re:
7.  Other:

**Correct data**

- 1.
- 2.
3. Heterocyclic MCHR1 Antagonists
- 4.
- 5.
- 6.
- 7.

*Bonnie L. Deppenbrock*  
 Bonnie L. Deppenbrock  
 Registration No.: 28,209

Date: 14 June 2006  
 GlaxoSmithKline  
 Five Moore Drive, P.O. Box 13398  
 Research Triangle Park, NC 27709  
 Phone: 919-483-1577  
 Fax: 919-483-7988

I hereby certify that this correspondence is being facsimile transmitted to  
 (571) 273-8300 on June 15, 2006.

*Patty Wilson*  
 Patty Wilson



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://uspto.gov)

*W/M LBD / Party*

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE RECD	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/552,232	10/07/2005	1623	3100 ✓	PR60211USW	49 ✓	1 ✓	

23347

GLAXOSMITHKLINE  
 CORPORATE INTELLECTUAL PROPERTY, MAI B475  
 FIVE MOORE DR., PO BOX 13398  
 RESEARCH TRIANGLE PARK, NC 27709-3398

CONFIRMATION NO. 6784

## FILING RECEIPT



\*OC000000018935222\*

Date Mailed: 06/02/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt Incorporating the requested corrections (if appropriate).

 Applicant(s)

Kevin K Barvian, Durham, NC;  
 Andrew J Carpenter, Durham, NC;  
 Joel P Cooper, Durham, NC;  
 Paul L Feldman, Durham, NC;  
 Dulce M Garrido, Durham, NC;  
 Yu C Guo, Durham, NC;  
 Anthony L Handlon, Durham, NC;  
 Donald L Hertzog, Durham, NC;  
 Clifton E Hyman, Durham, NC;  
 Andrew J Peat, Durham, NC;  
 Gregory E Peckham, Durham, NC;  
 Jason D Speake, Durham, NC;  
 William R Swain, Durham, NC;  
 Francis X Tavares, Durham, NC;  
 Huiqiang J Zhou, Durham, NC;

Power of Attorney: The patent practitioners associated with Customer Number 23347.


 Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/10518 04/06/2004 \*  
 which claims benefit of 60/462,292 04/11/2003

(\*Data provided by applicant is not consistent with PTO records.)

 Foreign Applications

If Required, Foreign Filing License Granted: 05/24/2006



The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/552,232**

**Projected Publication Date:** 08/31/2006

**Non-Publication Request:** No

**Early Publication Request:** No

**Title**

*Analogues*  
Heterocyclic mchr1 antagonists

**Preliminary Class**

514

## **PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

### **LICENSE FOR FOREIGN FILING UNDER**

**Title 35, United States Code, Section 184**

**Title 37, Code of Federal Regulations, 5.11 & 5.15**